Home » Amgen’s Bone Drug Gets Final Approval From UK Cost Agency
Amgen’s Bone Drug Gets Final Approval From UK Cost Agency
Amgen Inc.’s bone-strengthening drug Prolia should be provided to women at risk of fractures who can’t take existing drugs, said a UK agency that advises the state-run National Health Service on cost-effective treatments.
San Francisco Chronicle
San Francisco Chronicle
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May